Skip to main content

For health-system medicines leaders

Make the evidence-to-action thread visible without replacing authority.

For authorised medicines, pharmacy, finance, quality and transformation teams examining one governed workflow, its evidence, decisions, owners and blockers.

Map one workflowUnderstand PHARMORIS
Audience | Authorised medicines, pharmacy, finance and transformation teamsData | No patient-identifiable information through this siteAuthority | Local governance and professional duties prevail

One working thread

Start where a signal currently loses ownership.

A useful workflow map identifies the source, limitation, decision, responsible role, next action, blocker and review point. It does not turn software into a professional or commissioning authority.

01

Signal

Which evidence or operational event creates a need to review?

02

Decision

Which authorised role can accept, reject, defer or request more evidence?

03

Follow-through

Who owns the next action and how is completion or failure reviewed?

Before any evaluation

Product, security, clinical-safety and local-authority gates remain separate.

A conversation does not authorise a pilot or deployment. Any future PHARMORIS evaluation would require an exact version, defined intended use, source rights, information-governance and security scope, clinical-safety assessment where applicable, procurement route and adopter approval.

Human decision requiredProceed only inside an evidenced and governed scope.
  1. 01

    Define

    Workflow, users, environment, sources, decision rights and exclusions.

  2. 02

    Evidence

    Exact candidate, controls, failures, permissions and assurance route.

  3. 03

    Authorise

    The adopter's own governance, procurement and go-live decisions.

Review output

A decision map, not a deployment claim.

The output may identify a bounded next review, a missing evidence source, an ownership gap or a justified stop. It is not proof of clinical benefit, savings, adoption or production readiness.

Questions and boundaries

Useful questions before we start.

01Can a workflow be discussed without patient data?

Yes. Start with roles, triggers, decisions, hand-offs, blockers and measures. Do not send patient-identifiable or confidential clinical information through the website.

02Does a review replace local governance?

No. Professional duties, clinical-safety work, information governance, procurement and adopter approval remain with the relevant authorised organisations and people.

03What does NEUVIOR claim today?

A bounded review route and a controlled, non-production PHARMORIS development programme. No NHS deployment, clinical validation, customer adoption or production readiness is claimed.

Start safely

Describe the workflow without sending patient or confidential clinical data.

State the role, decision, evidence gap and intended operational outcome.

Start a scoped conversationReview assurance status